has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to US$179 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback